Telomere biology of pediatric cancer

Cancer Investigation

Volumn 25, Issue 3, 2007, Pages 197-208

  Tabori, Uri ^a   Dome, Jeffrey S ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

ALT; Assay; Childhood; Prognostic factor; Telomerase; Therapy

Indexed keywords

BIBR 1532; BRACO 19; CANCER VACCINE; COMPLEMENTARY RNA; GRN 163L; MESSENGER RNA; NUCLEOTIDE; OLIGONUCLEOTIDE; ONCOLYTIC VIRUS; RHPS 4; RHPS4; RIBOZYME; SMALL INTERFERING RNA; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESTATIN; TMPYP 4; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BIOASSAY; BIOLOGY; BRAIN TUMOR; CANCER CELL; CELL IMMORTALIZATION; CELL PROLIFERATION; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPENDYMOMA; EWING SARCOMA; GENE EXPRESSION; GENETIC RECOMBINATION; GLIOBLASTOMA; GLIOMA; HEPATOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MEDULLOBLASTOMA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; NUCLEOTIDE REPEAT; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETINOBLASTOMA; REVIEW; SARCOMA; SOLID TUMOR; SOUTHERN BLOTTING; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; CHILD; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHILD; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RECOMBINATION, GENETIC; TELOMERASE; TELOMERE;

EID: 34347272704     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701208683     Document Type: Review

References (130)

1. Hanahan, D.;Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100 (1), 57-70.
2. de Lange, T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19 (18), 2100-2110.
3. Griffith, J.D.; Comeau, L.; Rosenfield, S.; Stansel, R.M.; Bianchi, A.; Moss, H.; de Lange, T. Mammalian telomeres end in a large duplex loop. Cell 1999, 97, 503-514.
4. Smogorzewska, A.; Karlseder, J.; Holtgreve-Grez, H.; Jauch, A.; de Lange, T. DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr. Biol. 2002, 12 (19), 1635-1644.
5. Takai, H.; Smogorzewska, A.; de Lange, T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 2003, 13 (17), 1549-1556.
6. d'Adda di Fagagna, F.; Reaper, P.M.; Clay-Farrace, L.; Fiegler, H.; Carr, P.; von Zglinicki, T.; Saretzki, G.; Carter, N.P.; Jackson, S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426 (6963), 194-198.
7. Bakkenist, C.J.; Drissi, R.; Wu, J.; Kastan, M.B.; Dome, J.S. Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. Cancer Res. 2004, 64 (11), 3748-3752.
8. Harley, C.B. Telomere loss: mitotic clock or genetic time bomb. Mutat. Res. 1991, 256, 271-282.
9. Hara, E.; Tsurui, H.; Shinozaki, A.; Nakada, S.; Oda, K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochem. Biophys. Res. Commun. 1991, 179 (1), 528-534.
10. Shay, J.W.; Pereira-Smith, O.M.; Wright, W.E. A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell Res. 1991, 196 (1), 33-39.
11. Shay, J.W.; Wright, W.E.; Brasiskyte, D.; Van Der Haegen, B.A. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene 1993, 8 (6), 1407-1413.
12. Bodnar, A.G.; Ouellette, M.; Frolkis, M.; Holt, S.E.; Chiu, C.P.; et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279 (5349), 349-352.
13. Vaziri, H.; Benchimol, S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 1998, 8 (5), 279-282.
14. Counter, C.M.; Meyerson, M.; Eaton, E.N.; Ellisen, L.W.; Caddle, S.D.; Haber, D.A.; Weinberg, R.A. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998, 16 (9), 1217-1222.
15. Nakamura, T.M.; Morin, G.B.; Chapman, K.B.; Weinrich, S.L.; Andrews, W.H.; Lingner, J.; Harley, C.B.; Cech, T.R. Telomerase catalytic subunit homologs from fission yeast and human [see comments]. Science 1997, 277 (5328), 955-959.
16. Meyerson, M.; Counter, C.M.; Eaton, E.N.; Ellisen, L.W.; Steiner, P.; et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90 (4), 785-795.
17. Feng, J.; Funk, W.D.; Wang, S.S.; Weinrich, S.L.; Avilion, A.A.; et al. The RNA component of human telomerase. Science 1995, 269 (5228), 1236-1241.
18. Avilion, A.A.; Piatyszek, M.A.; Gupta, J.; Shay, J.W.; Bacchetti, S.; Greider, C.W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 1996, 56 (3), 645-650.
19. Takakura, M.; Kyo, S.; Kanaya, T.; Tanaka, M.; Inoue, M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 1998, 58 (7), 1558-1561.
20. Blasco, M.A.; Rizen, M.; Greider, C.W.; Hanahan, D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat. Genet. 1996, 12 (2), 200-204.
21. Soder, A.I.; Hoare, S.F.; Muir, S.; Going, J.J.; Parkinson, E.K.; Keith, W.N. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997, 14 (9), 1013-1021.
22. Yashima, K.; Maitra, A.; Timmons, C.F.; Rogers, B.B.; Pinar, H.; Shay, J.W.; Gazdar, A.F. Expression of the RNA component of telomerase in Wilms tumor and nephrogenic rest recapitulates renal embryogenesis. Hum. Pathol. 1998, 29 (5), 536-542.
23. Yi, X.; Tesmer, V.M.; Savre-Train, I.; Shay, J.W.; Wright, W.E. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Mol. Cell Biol. 1999, 19, 3989-3997.
24. Guilleret, I.; Yan, P.; Guillou, L.; Braunschweig, R.; Coindre, J.M.; Benhattar, J. The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation. Carcinogenesis 2002, 23 (12), 2025-2030.
25. Aisner, D.L.; Wright, W.E.; Shay, J.W. Telomerase regulation: not just flipping the switch. Curr. Opin. Genet. Dev. 2002, 12 (1), 80-85.
26. Kim, N.W.; Piatyszek, M.A.; Prowse, K.R.; Harley, C.B.; et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266 (5193), 2011-2015.
27. Shay, J.W.; Bacchetti, S. A survey of telomerase activity in human cancer. [Review] [51 refs]. Eur. J. Cancer 1997, 33 (5), 787-791.
28. Bryan, T.M.; Englezou, A.; Gupta, J.; Bacchetti, S.; Reddel, R.R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995, 14 (17), 4240-4248.
29. Bryan, T.M.; Englezou, A.; Dallapozza, L.; Dunham, M.A.; Reddel, R.R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 1997, 3 (11), 1271-1274.
30. Hakin-Smith, V.; Jellinek, D.A.; Levy, D.; Carroll, T.; Teo, M.; et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003, 361 (9360), 836-838.
31. Mehle, C.; Piatyszek, M.A.; Ljungberg, B.; Shay, J.W.; Roos, G. Telomerase activity in human renal cell carcinoma. Oncogene 1996, 13 (1), 161-166.
32. Lundblad, V.; Blackburn, E.H. An alternative pathway for yeast telomere maintenance rescues est1-senescence. Cell 1993, 73 (2), 347-360.
33. Teng, S.C.; Zakian, V.A. Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol. Cell Biol. 1999, 19 (12), 8083-8093.
34. Murnane, J.P.; Sabatier, L.; Marder, B.A.; Morgan, W.F. Telomere dynamics in an immortal human cell line. EMBO J. 1994, 13 (20), 4953-4962.
35. Dunham, M.A.; Neumann, A.A.; Fasching, C.L.; Reddel, R.R. Telomere maintenance by recombination in human cells. Nat. Genet. 2000, 26 (4), 447-450.
36. Bechter, O.E.; Zou, Y.; Shay, J.W.; Wright, W.E. Homologous recombination in human telomerase-positive and ALT cells occurs with the same frequency. EMBO Rep. 2003, 4 (12), 1138-1143.
37. Piatyszek, M.A.; Kim, N.W.; Weinrich, S.L.; Hiyama, K.; Hiyama, E.; Wright, W.E.; Shay, J.W. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci. 1995, 17, 1-15.
38. Dome, J.S.; Bockhold, C.A.; Li, S.M.; Baker, S.D.; Green, D.M.; Perlman, E.J.; Hill, D.A.; Breslow, N.E. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J. Clin. Oncol. 2005, 23 (36), 9138-9145.
39. Poremba, C.; Scheel, C.; Hero, B.; Christiansen, H.; Schaefer, K.L.; et al. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J. Clin. Oncol. 2000, 18 (13), 2582-2592.
40. Poremba, C.; Heine, B.; Diallo, R.; Heinecke, A.; Wai, D.; et al. Telomerase as a prognostic marker in breast cancer: highthroughput tissue microarray analysis of hTERT and hTR. J. Pathol. 2002, 198 (2), 181-189.
41. Yeager, T.R.; Neumann, A.A.; Englezou, A.; Huschtscha, L.I.; Noble, J.R.; Reddel, R.R. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999, 59 (17), 4175-4179.
42. Wu, G.; Jiang, X.; Lee, W.H.; Chen, P.L. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. Cancer Res. 2003, 63 (10), 2589-2595.
43. Montgomery, E.; Argani, P.; Hicks, J.L.; DeMarzo, A.M.; Meeker, A.K. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am. J. Pathol. 2004, 164 (5), 1523-1529.
44. Henson, J.D.; Hannay, J.A.; McCarthy, S.W.; Royds, J.A.; Yeager, T.R.; et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin. Cancer Res. 2005, 11 (1), 217-225.
45. Polychronopoulou, S.; Koutroumba, P. Telomere length and telomerase activity: variations with advancing age and potential role in childhood malignancies. J. Pediatr. Hematol. Oncol. 2004, 26 (6), 342-350.
46. Counter, C.M.; Gupta, J.; Harley, C.B.; Leber, B.; Bacchetti, S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995, 85 (9), 2315-2320.
47. Hiyama, K.; Hirai, Y.; Kyoizumi, S.; Akiyama, M.; Hiyama, E.; Piatyszek, M.A.; Shay, J.W.; Ishioka, S.; Yamakido, M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 1995, 155 (8), 3711-3715.
48. Chiu, C.P.; Dragowska ,W.; Kim, N.W.; Vaziri, H.; Yui, J.; Thomas, T.E.; Harley, C.B.; Lansdorp, P.M. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 1996, 14 (2), 239-248.
49. Ohyashiki, J.H.; Sashida, G.; Tauchi, T.; Ohyashiki, K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002, 21 (4), 680-687.
50. Hastie, N.D.; Dempster, M.; Dunlop, M.G.; Thompson, A.M.; Green, D.K.; Allshire, R.C. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990, 346, 866-868.
51. Vaziri, H.; Schachter, F.; Uchida, I.; Wei, L.; Zhu, X.; Effros, R.; Cohen, D.; Harley, C.B. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am. J. Hum. Genet. 1993, 52, 661-667.
52. Hodes, R.J.; Hathcock, K.S.; Weng, N.P. Telomeres in T and B cells. Nat. Rev. Immunol. 2002, 2 (9), 699-706.
53. Ohyashiki, J.H.; Ohyashiki, K.; Iwama, H.; Hayashi, S.; Toyama, K.; Shay, J.W. Clinical implications of telomerase activity levels in acute leukemia. Clin. Cancer Res. 1997, 3 (4), 619-625.
54. Engelhardt, M.; Ozkaynak, M.F.; Drullinsky, P.; Sandoval, C.; Tugal, O.; Jayabose, S.; Moore, M.S. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 1998, 12 (1), 13-24.
55. Malaska, J.; Sklenickova, M.; Krejci, K.; Fajkusova, L.; Bajer, M.; Hrstkova, H.; Fajkus, J. Telomerase activity and expression and telomere analysis in situ in the course of treatment of childhood leukemias. Blood Cells Mol. Dis. 2000, 26 (5), 534-539.
56. Cogulu, O.; Kosova, B.; Karaca, E.; Gunduz, C.; Ozkinay, F.; et al. Evaluation of Telomerase mRNA (hTERT) in Childhood Acute Leukemia. Leuk. Lymphoma 2004, 45 (12), 2477-2480.
57. Verstovsek, S.; Manshouri, T.; Smith, F.O.; Giles, F.J.; Cortes, J.; et al. Telomerase activity is prognostic in pediatric patients with acutemyeloid leukemia: comparison with adult acutemyeloid leukemia. Cancer 2003, 97 (9), 2212-2217.
58. Huh, H.J.; Huh, J.W.; Yoo, E.S.; Seong, C.M.; Lee, M.; Hong, K.S.; Chung, W.S. hTERT mRNA levels by real-time RT-PCR in acutemyelogenous leukemia. Am. J. Hematol. 2005, 79 (4), 267-273.
59. Adamson, D.J.; King, D.J.; Haites, N.E. Significant telomere shortening in childhood leukemia. Cancer Genet Cytogenet. 1992, 61 (2), 204-206.
60. Franco, S.; Ozkaynak, M.F.; Sandoval, C.; Tugal, O.; Jayabose, S.; Engelhardt, M.; Moore, M.A. Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia 2003, 17 (2), 401-410.
61. Hiyama, E.; Hiyama, K.; Yokoyama, T.; Matsuura, Y.; Piatyszek, M.A.; Shay, J.W. Correlating telomerase activity levels with human neuroblastoma outcomes [see comments]. Nat. Med. 1995, 1 (3), 249-255.
62. Brinkschmidt, C.; Poremba, C.; Christiansen, H.; Simon, R.; Schafer, K.L.; et al. Comparative genomic hybridation and telomerase activity analysis identify two biologically different groups of 4S neuroblastomas. Br. J. Cancer. 1998, 77 (12), 2223-2229.
63. Krams, M.; Hero, B.; Berthold, F.; Parwaresch, R.; Harms, D.; Rudolph, P. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am. J. Pathol. 2003, 162 (3), 1019-1026.
64. Poremba, C.; Hero, B.; Heine, B.; Scheel, C.; Schaefer, K.L.; Christiansen, H.; et al. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med. Pediatr. Oncol. 2000, 35 (6), 651-655.
65. Choi, L.M.; Kim, N.W.; Zuo, J.J.; Gerbing, R.; Stram, D.; et al. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma. Med. Pediatr. Oncol. 2000, 35 (6), 647-650.
66. Krams, M.; Claviez, A.; Heidorn, K.; Krupp, G.; Parwaresch, R.; Harms, D.; Rudolph, P. Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas. Am. J. Pathol. 2001, 159 (5), 1925-1932.
67. Hiyama, E.; Hiyama, K.; Nishiyama, M.; Reynolds, C.P.; Shay, J.W.; Yokoyama, T. Differential gene expression profiles between neuroblastomas with high telomerase activity and low telomerase activity. J. Pediatr. Surg. 2003, 38 (12), 1730-1734.
68. Hiyama, E.; Hiyama, K.; Yokoyama, T.; Ichikawa, T.; Matsuura, Y. Length of telomeric repeats in neuroblastoma: correlation with prognosis and other biological characteristics. Jpn. J. Cancer Res. 1992, 83 (2), 159-164.
69. Dome, J.S.; Chung, S.; Bergemann, T.; Umbricht, C.B.; Saji, M.; et al. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res. 1999, 59 (17), 4301-4307.
70. Hiyama, E.; Yamaoka, H.; Matsunaga, T.; Hayashi, Y.; Ando, H.; Suita, S.; et al. High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma. Br. J. Cancer. 2004, 91 (5), 972-979.
71. Gupta, J.; Han, L.P.; Wang, P.; Gallie, B.L.; Bacchetti, S. Development of retinoblastoma in the absence of telomerase activity. J. Natl. Cancer Inst. 1996, 88 (16), 1152-1157.
72. Neumann, A.A.; Reddel, R.R. Telomere maintenance and cancer - look, no telomerase. Nat. Rev. Cancer. 2002, 2 (11), 879-884.
73. Ulaner, G.A.; Huang, H.Y.; Otero, J.; Zhao, Z.; Ben Porat, L.; et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 2003, 63 (8), 1759-1763.
74. Aue, G.; Muralidhar, B.; Schwartz, H.S.; Butler, M.G. Telomerase activity in skeletal sarcomas. Ann. Surg. Oncol. 1998, 5 (7), 627-634.
75. Sangiorgi, L.; Gobbi, G.A.; Lucarelli, E.; Sartorio, S.M.; Mordenti, M.; et al. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int. J. Cancer. 2001, 95 (3), 156-161.
76. Scheel, C.; Schaefer, K.L.; Jauch, A.; Keller, M.; Wai, D.; et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene. 2001, 20 (29), 3835-3844.
77. Kido, A.; Schneider-Stock, R.; Hauptmann, K.; Roessner, A. Telomerase activity in juxtacortical and conventional high-grade osteosarcomas: correlation with grade, proliferative activity and clinical response to chemotherapy. Cancer Lett. 2003, 196 (1), 109-115.
78. Sanders, R.P.; Drissi, R.; Billups, C.A.; Daw, N.C.; Valentine, M.B.; Dome, J.S. Telomerase expression predicts unfavorable outcome in osteosarcoma. J. Clin. Oncol. 2004, 22 (18), 3790-3797.
79. Sotillo-Pineiro, E.; Sierrasesumaga, L.; Patino-Garcia, A. Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatr. Res. 2003,
80. Ohali, A.; Avigad, S.; Cohen, I.J.; Meller, I.; Kollender, Y.; et al. Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J. Clin. Oncol. 2003, 21 (20), 3836-3843.
81. Ulaner, G.A.; Hoffman, A.R.; Otero, J.; Huang, H.Y.; Zhao, Z.; et al. Divergent patterns of telomere maintenance mechanisms among human sarcomas: Sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer. 2004, 41 (2), 155-162.
82. Yan, P.; Benhattar, J.; Coindre, J.M.; Guillou, L. Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int. J. Cancer. 2002, 98 (6), 851-856.
83. Miyoshi, Y.; Tsukinoki, K.; Imaizumi, T.; Yamada, Y.; Ishizaki, T.; et al. Telomerase activity in oral cancer. Oral Oncol. 1999, 35 (3), 283-289.
84. Yoo, J.; Robinson, R.A. Expression of telomerase activity and telomerase RNA in human soft tissue sarcomas. Arch. Pathol. Lab. Med. 2000, 124 (3), 393-397.
85. Schneider-Stock, R.; Boltze, C.; Jager, V.; Epplen, J.; Landt, O.; Peters, B.; Rys, J.; Roessner, A. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J. Pathol. 2003, 199 (4), 517-525.
86. Hiraga, S.; Ohnishi, T.; Izumoto, S.; Miyahara, E.; Kanemura, Y.; Matsumura, H.; Arita, N. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 1998, 58 (10), 2117-2125.
87. Didiano, D.; Shalaby, T.; Lang, D.; Grotzer, M.A. Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-Oncol. 2004, 6 (1), 1-8.
88. Fan, X.;Wang, Y.; Kratz, J.; Brat, D.J.; Robitaille, Y.; Moghrabi, A.; et al.G. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am. J. Pathol. 2003, 162 (6), 1763-1769.
89. Chong, E.Y.; Lam, P.Y.; Poon, W.S.; Ng, H.K. Telomerase expression in gliomas including the nonastrocytic tumors. Hum. Pathol. 1998, 29 (6), 599-603.
90. Falchetti, M.L.; Larocca, L.M.; Pallini, R. Telomerase in brain tumors. Childs Nerv. Syst. 2002, 18(3-4), 112-117.
91. Tabori, U.; Vukovic, B.; Zielenska, M.; Hawkins, C.; Braude, I.; et al. The role of telomere maintenance in the spontaneous growth arrest of pediatric low grade gliomas. Neoplasia 2006, 8(2), 136-142.
92. Fukushima, T.; Yoshino, A.; Katayama, Y.;Watanabe, T.; Kusama, K.; Moro, I. Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level. Cancer Lett. 2002, 187 (1-2), 191.
93. Langford, L.A.; Piatyszek, M.A.; Xu, R.; Schold, S.C.J.; Shay, J.W. Telomerase activity in human brain tumours. Lancet 1995, 346 (8985), 1267-1268.
94. Morii, K.; Tanaka, R.; Onda, K.; Tsumanuma, I.; Yoshimura, J. Expression of telomerase RNA, telomerase activity, and telomere length in human gliomas. Biochem. Biophys. Res. Commun. 1997, 239 (3), 830-834.
95. Tchirkov, A.; Rolhion, C.; Kemeny, J.L.; Irthum, B.; Puget, S.; et al. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br. J. Cancer. 2003, 88 (4), 516-520.
96. Alonso, M.M.; Fueyo, J.; Shay, J.W.; Aldape, K.D.; Jiang, H.; et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J. Natl. Cancer Inst. 2005, 97 (21), 1589-1600.
97. Tabori, U.; Ma, J.; Carter, M.; Zielenska, M.; Rutka, J.; et al. HTERT expression predicts progression and survival in pediatric intracranial ependymoma. J. Clin. Oncol. 2006, 24 (10), 1522-1528.
98. Marusic, L.; Anton, M.; Tidy, A.; Wang, P.; Villeponteau, B.; Bacchetti, S. Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability. Mol. Cell Biol. 1997, 17 (11), 6394-6401.
99. Hahn, W.C.; Stewart, S.A.; Brooks, M.W.; York, S.G.; Eaton, E.; et al. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 1999, 5, 1164-1170.
100. Zhang, X.; Mar, V.; Zhou, W.; Harrington, L.; Robinson, M.O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999, 13, 2388-2399.
101. Nosrati, M.; Li, S.; Bagheri, S.; Ginzinger, D.; Blackburn, E.H.; Debs, R.J.; Kashani-Sabet, M. Antitumor activity of systemically delivered ribozymes targetingmurine telomerase RNA. Clin. Cancer Res. 2004, 10 (15), 4983-4990.
102. Li, S.; Rosenberg, J.E.; Donjacour, A.A.; Botchkina, I.L.; Hom, Y.K.; Cunha, G.R.; Blackburn, E.H. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res. 2004, 64 (14), 4833-4840.
103. Shay, J.W.; Wright, W.E. Telomerase: a target for cancer therapeutics. Cancer Cell 2002, 2 (4), 257-265.
104. Corey, D.R. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 2002, 21 (4), 631-637.
105. Kelland, L.R. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics-current status and future prospects. Eur. J. Cancer. 2005, 41 (7), 971-979.
106. Herbert, B.S.; Pongracz, K.; Shay, J.W.; Gryaznov, S.M. Oligonucleotide N3′->P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 2002, 21 (4), 638-642.
107. Herbert, B.S.; Gellert, G.C.; Hochreiter, A.; Pongracz, K.; Wright, W.E.; et al. Lipid modification of GRN163, an N3′->P5′ thiophosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005, 24 (33), 5262-5268.
108. Gellert, G.C.; Dikmen, Z.G.; Wright, W.E.; Gryaznov, S.; Shay, J.W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 2005, 1-9.
109. Dikmen, Z.G.; Gellert, G.C.; Jackson, S.; Gryaznov, S.; Tressler, R.; et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 2005, 65 (17), 7866-7873.
110. Damm, K.; Hemmann, U.; Garin-Chesa, P.; Hauel, N.; Kauffmann, I.; et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001, 20 (24), 6958-6968.
111. Pascolo, E.; Wenz, C.; Lingner, J.; Hauel, N.; Priepke, H.; et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 2002, 277 (18), 15566-15572.
112. Ward, R.J.; Autexier, C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol. Pharmacol. 2005, 68 (3), 779-786.
113. El-Daly, H.; Kull, M.; Zimmermann, S.; Pantic, M.; Waller, C.F.; Martens, U.M. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005, 105 (4), 1742-1749.
114. Grand, C.L.; Han, H.; Munoz, R.M.; Weitman, S.; Von Hoff, D.D.; Hurley, L.H.; Bearss, D.J. The cationic porphyrin TMPyP4 downregulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol. Cancer Ther. 2002, 1 (8), 565-573.
115. Burger, A.M.; Dai, F.; Schultes, C.M.; Reszka, A.P.; Moore, M.J.; Double, J.A.; Neidle, S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005, 65 (4), 1489-1496.
116. Cookson, J.C.; Dai, F.; Smith, V.; Heald, R.A.; Laughton, C.A.; Stevens, M.F.; Burger, A.M. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8, 13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol. Pharmacol. 2005, 68 (6), 1551-1558.
117. Binz, N.; Shalaby, T.; Rivera, P.; Shin-Ya, K.; Grotzer, M.A. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. Eur. J. Cancer. 2005, 41 (18), 2873-2881.
118. Gowan, S.M.; Heald, R.; Stevens, M.F.; Kelland, L.R. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with g-quadruplexes. Mol. Pharmacol. 2001, 60 (5), 981-988.
119. Pennarun, G.; Granotier, C.; Gauthier, L.R.; Gomez, D.; Hoffschir, F.; et al. Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. Oncogene 2005, 24 (18), 2917-2928.
120. Tahara, H.; Shin-Ya, K.; Seimiya, H.; Yamada, H.; Tsuruo, T.; Ide, T. G-quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3′ telomeric overhang in cancer cells. Oncogene 2005,
121. Rha, S.Y.; Izbicka, E.; Lawrence, R.; Davidson, K.; Sun, D.; et al. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. Clin. Cancer Res. 2000, 6 (3), 987-993.
122. Vonderheide, R.H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002, 21 (4), 674-679.
123. Kim, E.; Kim, J.H.; Shin, H.Y.; Lee, H.; Yang, J.M.; et al. AdmTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther. 2003, 14 (15), 1415-1428.
124. Huang, Q.; Zhang, X.;Wang, H.; Yan, B.; Kirkpatrick, J.; Dewhrist, M.W.; Li, C.Y. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin. Cancer Res. 2004, 10 (4), 1439-1445.
125. Abdul-Ghani, R.; Ohana, P.; Matouk, I.; Ayesh, S.; Ayesh, B.; et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol. Ther. 2000, 2 (6), 539-544.
126. Koga, S.; Hirohata, S.; Kondo, Y.; Komata, T.; Takakura, M.; Inoue, M.; Kyo, S.; Kondo, S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum. Gene Ther. 2000, 11 (10), 1397-1406.
127. Koga, S.; Hirohata, S.; Kondo, Y.; Komata, T.; Takakura, M.; et al. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res. 2001, 21 (3B), 1937-1943.
128. Gu, J.; Kagawa, S.; Takakura, M.; Kyo, S.; Inoue, M.; Roth, J.A.; Fang, B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000, 60 (19), 5359-5364.
129. Majumdar, A.S.; Hughes, D.E.; Lichtsteiner, S.P.; Wang, Z.; Lebkowski, J.S.; Vasserot, A.P. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther. 2001, 8 (7), 568-578.
130. Plumb, J.A.; Bilsland, A.; Kakani, R.; Zhao, J.; Glasspool, R.M.; et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001, 20 (53), 7797-7803.